Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.

The conversation is about starting finasteride for hair loss, with concerns about high free testosterone and potential side effects like gynecomastia. The user plans to address vitamin deficiencies before beginning the treatment.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

A user reports high DHT levels despite taking finasteride and is concerned about inconsistent blood test results. They also take modafinil, vitamin D, and magnesium supplements.

An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.

The post and conversation are about the user's high testosterone levels and their worsening hair loss despite trying various treatments. They are considering using low doses of anti-androgens to lower their testosterone levels as a potential solution.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

Teak leaf extract shows potential as a mild hair growth promoter for androgenic alopecia, with similar positive trends to minoxidil but without significant side effects. It can be made at home using dried teak leaves and ethanol, though its effectiveness compared to other treatments like finasteride is debated.

User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.

Hair loss discussion involved Finasteride, Minoxidil, and RU58841. User experienced sudden shedding after 1.5 years of Finasteride and Minoxidil use, seeking advice.

A user is considering using both oral and topical finasteride for hair loss, despite having elevated liver enzymes. They currently use a topical spray with finasteride and minoxidil and are seeking advice on whether using both forms is advisable.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.